PureTech Health PLC PRTC Immuno-Oncology Programme Granted US Patent
09 Julio 2019 - 3:32AM
RNS Non-Regulatory
TIDMPRTC
PureTech Health PLC
09 July 2019
9 July 2019
PureTech Health plc
PureTech Announces Issuance of US Patent Covering Compositions
of Matter for Immuno-Oncology Programme Targeting Galectin-9
Fully human, potentially first-in-class, monoclonal antibody
designed to target a fundamental immunosuppressive mechanism in
hard-to-treat cancers
PureTech Health plc (LSE: PRTC) ("PureTech"), an advanced
biopharmaceutical company developing novel medicines for
dysfunctions of the Brain-Immune-Gut (BIG) axis, today announced
that the United States Patent and Trademark Office (USPTO) has
issued US Patent No. 10,344,091 to support the Company's internal
immuno-oncology product candidate, LYT-200. The patent covers
compositions of matter directed to fully human anti-galectin-9
antibodies, which PureTech intends to develop for historically
difficult-to-treat cancers including pancreatic, colorectal, and
cholangiocarcinoma, among other cancer types. PureTech intends to
file an investigational new drug (IND) application for LYT-200 in
the first half of 2020.
"PureTech's galectin-9 antibody has been designed to address the
challenges encountered with current immuno-oncology treatments due
to redundancies in the immunosuppressive tumour microenvironment.
Our now patented antibody composition leverages a new mechanism of
action to disrupt the immunosuppressive environment, potentially
enabling the body's immune system to attack cancers that have
historically been hard to treat," said Joe Bolen, PhD, chief
scientific officer of PureTech. "This patent provides important
coverage for our immuno-oncology programme, and we look forward to
continuing the development of LYT-200 to address the tremendous
patient need that exists."
Galectin-9 induces robust immunosuppression that allows tumours
to evade immune system attack. It is a foundational immune
modulator that is expressed in the tumour microenvironment, on
tumour cells, and in the blood of cancer patients, globally
inducing and maintaining immunosuppression in cancer. High
galectin-9 expression has been demonstrated in a number of patient
tumour samples, including those that do not respond well to current
checkpoint inhibitors. By blocking galectin-9, PureTech's
potentially first-in-class, fully human, monoclonal antibody is
designed to intercept the immunosuppressive pathways that
galectin-9 stimulates, potentially enabling an immune-mediated
response against tumours. While existing therapies have not been
sufficiently effective in the treatment of aggressive tumours,
PureTech's approach has shown favourable drug properties and safety
in pre-clinical models, and it is being explored as both a
single-agent and in combination with other modalities for cancer
treatment, including other immunotherapies and chemotherapies.
About LYT-200
PureTech's immuno-oncology programme, LYT-200, is a fully human,
potentially first-in-class, IgG4 monoclonal antibody designed to
target galectin-9, which is a fundamental immunosuppressive
mechanism in hard-to-treat cancers such as pancreatic, colorectal,
and cholangiocarcinoma, among other tumour types. LYT-200 has
demonstrated proof-of-concept in both mouse and preclinical human
cancer models, indicating that targeting galectin-9 activates T
cells in tumours and reduces tumour growth, which could
significantly extend survival. These data suggest that LYT-200 has
strong potential to be used as both a monotherapy and in
combination with existing immuno-oncology therapies. PureTech
intends to file an investigational new drug (IND) application for
LYT-200 in the first half of 2020.
About PureTech
PureTech (LSE: PRTC) is an advanced biopharmaceutical company
developing highly differentiated medicines for dysfunctions of the
Brain-Immune-Gut (BIG) axis. The Company has gained deep insights
into the connection between these systems and the resulting role in
diseases that have been resistant to established therapeutic
approaches. By harnessing this emerging field of human biology,
PureTech is developing new categories of medicines with the
potential to have great impact on people with serious
disorders.
PureTech is advancing a rich pipeline of innovative therapies
with an unbiased, nimble, and capital efficient R&D model
across its affiliates and its internal R&D pipeline. PureTech's
pipeline comprises more than two dozen product candidates,
including several clinical-stage programmes, one product that has
been cleared by the US Food and Drug Administration (FDA), and a
second product candidate that has been filed with the FDA for
review. The PureTech pipeline includes ground-breaking platforms
and therapeutic candidates that were developed in collaboration
with some of the world's leading experts.
PureTech's internal pipeline is centred on lymphatic targeting
and tissue-selective immunomodulation for the potential treatment
of immune and central nervous system disorders, lymphatic
conditions, and cancers. The Company is advancing multiple
platforms to enable oral administration of therapies directly into
the lymphatic system, regulate lymphatic flow and function, and
target immunosuppressive mechanisms in oncology. For more
information, visit www.puretechhealth.com or connect with us on
Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media US media
Allison Mead Talbot Ben Atwell, Rob Winder Tom Donovan
+1 617 651 3156 +44 (0) 20 3727 1000 +1 857 559 3397
amt@puretechhealth.com ben.atwell@FTIconsulting.com tom@tenbridgecommunications.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAZMGGNGRLGLZZ
(END) Dow Jones Newswires
July 09, 2019 04:32 ET (08:32 GMT)
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024